Evidence map›Paper›PMID 34794903›Full record

ArticleClinical colorectal cancer2022

Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer.

Nicolette Taku, Y Nancy Yi-Qian, George J Chang, Ethan B Ludmir, Kanwal Pratap Singh Raghav, Miguel A Rodriguez-Bigas, Emma Brey Holliday, Grace L Smith, Bruce D Minsky, Michael J Overman and 11 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical colorectal cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Mutational and co-mutational landscape of early onset colorectal cancer.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Nicolette TakuDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Y Nancy Yi-QianDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
George J ChangDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ethan B LudmirDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Kanwal Pratap Singh RaghavDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Miguel A Rodriguez-BigasDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Emma Brey HollidayDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Grace L SmithDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Bruce D MinskyDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Michael J OvermanDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Craig MessickDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
David Boyce-FappianoDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Albert C KoongDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
John Michael SkibberDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Eugene Jon KoayDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Arvind DasariDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Cullen M TaniguchiDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Brian K BednarskiDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Van K MorrisDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Scott KopetzDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Prajnan DasDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: prajdas@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Fellow and Resident Radiation Oncology iNtensive Training in Imaging and Informatics to Empower Research Careers (FRONTI2ER)R25EB025787 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAS, PRAJNAN, FULLER, CLIFTON DAVID · 2018 to 2022
$535k
NCI NIH HHS P30 CA016672NIBIB NIH HHS R25 EB025787
6 · The paper itself

Abstract

purposeThere has been an increase in the incidence of rectal cancer diagnosed in young adults (age < 50 years). We evaluated outcomes among young adults treated with pre-operative long course chemoradiation (CRT) and total mesorectal excision (TME).

methodsThe medical records of 219 patients, age 18-49, with non-metastatic, cT3-4, or cN1-2 rectal adenocarcinoma treated from 2000 to 2017 were reviewed for demographic and treatment characteristics, as well as pathologic and oncologic outcomes. The Kaplan-Meier test, log-rank test, and Cox regression analysis were used to evaluate survival outcomes.

resultsThe median age at diagnosis was 44 years. CRT followed by TME and post-operative chemotherapy was the most frequent treatment sequence (n = 196), with FOLFOX (n = 115) as the predominant adjuvant chemotherapy. There was no difference in sex, stage, MSS/pMMR, or pCR by age (< 45 years [n = 111] vs. ≥ 45 years [n = 108]). The 5-year rates of DFS were 77.2% for all patients, 69.8% for age < 45 years and 84.7% for age ≥ 45 years (P = .01). The 5-year rates of OS were 89.6% for all patients, 85.1% for patients with age < 45 years and 94.3% for patients with age ≥ 45 years (P = .03). Age ≥ 45 years was associated with a lower risk of disease recurrence or death on multivariable Cox regression analysis (HR = 0.55, 95% CI 0.31-0.97, P = .04).

conclusionAmong young adults, patients with age < 45 years had lower rates of DFS and OS, compared to those with age ≥ 45 years. These outcomes could serve as a benchmark by which to evaluate newer treatment approaches.

Indexed as

Neoadjuvant TherapyRectal NeoplasmsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBenchmarkingChemoradiotherapyDisease-Free SurvivalHumansMiddle AgedNeoplasm StagingRetrospective StudiesTreatment OutcomeYoung AdultColorectal cancerGastrointestinal cancerRadiation oncologySurgical oncologyYoung adults

Identifiers

PMID34794903
PMCPMC8917971
OpenAlexW3206501307

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.